Effects of 2α,3α,24-trihydroxy-12-alkene-28-ursolic acid extracted from the root of Actinidia eriantha Benth on human colon cancer cells

Main Article Content

Lei Wang
Lan Chen
Huaihan Deng
Jin Zhou


colon cancer; 2α,3α,24-trihydroxy-12-alkene-28-ursolic acid; proliferation; invasion; migration; apoptosis


Aim: We aimed to evaluate the effects of 2α,3α,24-trihydroxy-12-alkene-28-ursolic acid (TEOA) on the proliferation, invasion, migration and apoptosis of human colon cancer cell line HCT116 as well as the mechanism. Methods: HCT116 cells were treated with different concentrations of TEOA (0 μM, 20 μM, 40 μM, 60 μM). The cell proliferation was detected by MTT and colony formation assays. The migration and invasion were tested by Transwell assay, and the apoptosis was studied by flow cytometry. Autophagic vacuoles were observed by fluorescence microscopy. The protein expressions of apoptosis markers caspase-9 and PARP as well as autophagy markers LC3-II and p62 were detected by Western blot. Results: TEOA had growth inhibitory effects on HCT116 cells in time- and dose-dependent manners. The cell proliferation was significantly inhibited after TEOA treatment, and the size and number of colonies were significantly lower than those of control cells. After TEOA treatment, the invasion and migration abilities of HCT116 cells decreased significantly. TEOA caused apoptosis of HCT116 cells dose-dependently. After 48 h of treatment, TEOA activated the protein expressions of caspase-9, PARP, LC3-II and p62, which also increased with rising dose. Conclusion: TEOA can significantly inhibit the proliferation, invasion and migration of human colon cancer HCT116 cells, and promote their apoptosis, probably being related to autophagy.


Download data is not yet available.
Abstract 43 | PDF Downloads 16


1. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2017; 11: 117-8.
2. Zhang Y, Chen Z, Li J. The current status of treatment for colorectal cancer in China: A systematic review. Medicine 2017; 96: e8242.
3. Larki P, Gharib E, Taleghani MY, et al. Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting the Concept of Tumoral Heterogeneity. Cell J 2017; 19: 113-7.
4. Chida K, Nakanishi K, Shomura H, et al. Spontaneous regression of transverse colon cancer: a case report. Surg Case Rep 2017; 3: 65.
5. Destri GL, Puzzo L, Russo AE, Ferraù F, Di Cataldo A, Puleo S. Synchronous hepatic metastasis and metachronous Krukenberg tumor from advanced colon cancer. A case report with an unexpected disease-free survival. Int J Surg Case Rep 2017; 30: 138-41.
6. Rivera DE, Ocampo YC, Castro JP, Barrios L, Diaz F, Franco LA. A screening of plants used in Colombian traditional medicine revealed the anti-inflammatory potential of Physalis angulata calyces. Saudi J Biol Sci 2019; 26: 1758-66.
7. Xiao S, Tian Z, Wang Y, Si L, Zhang L, Zhou D. Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. Med Res Rev 2018; 38: 951-76.
8. Song PF, Zhu YD, Ma HY, et al. Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Fitoterapia 2019; 137: 104199.
9. Zhang D, Gao C, Li R, Zhang L, Tian J. TEOA, a triterpenoid from Actinidia eriantha, induces autophagy in SW620 cells via endoplasmic reticulum stress and ROS-dependent mitophagy. Arch Pharm Res 2017; 40: 579-91.
10. Li Z, Yu JB, Wang T, Liu F, Gao X, Cheng MA. [Clinical epidemiological analysis of 849 cases of colorectal cancer in Mudanjiang region of China]. Cancer Res Clin 2017; 29: 266-8, 75.
11. Banerjee A, Pathak S, Subramanium VD, Dharanivasan G, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today 2017; 22: 1224-32.
12. Tauriello DVS, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018; 554: 538-43.
13. Hsu HH, Chen MC, Day CH, et al. Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation. World J Gastroenterol 2017; 23: 1171-9.
14. Peng X, Pan K, Zhao W, et al. NPTX1 inhibits colon cancer cell proliferation through down-regulating cyclin A2 and CDK2 expression. Cell Biol Int 2018; 42: 589-97.
15. Seo JS, Choi YH, Moon JW, Kim HS, Park SH. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol 2017; 18: 14.
16. Sun A, Wei J, Childress C, et al. The E3 ubiquitin ligase NEDD4 is an LC3-interactive protein and regulates autophagy. Autophagy 2017; 13: 522-37.
17. Zheng S, Han F, Shi Y, Wen L, Han D. Single-Prolonged-Stress-Induced Changes in Autophagy-Related Proteins Beclin-1, LC3, and p62 in the Medial Prefrontal Cortex of Rats with Post-traumatic Stress Disorder. J Mol Neurosci 2017; 62: 43-54.
18. Choi YK, Cho SG, Choi YJ, et al. SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes. Oncotarget 2017; 8: 88386-400.
19. Zhang J, Yang Z, Dong J. P62: An emerging oncotarget for osteolytic metastasis. J Bone Oncol 2016; 5: 30-7.